Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1420 | Esophageal temperature monitoring probe Wiki | 1.00 |
| drug4474 | ensoETM. Esophageal cooling during AF ablation Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004937 | Esophageal Fistula NIH | 1.00 |
| D005402 | Fistula NIH | 0.71 |
| D001281 | Atrial Fibrillation NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004757 | Paroxysmal atrial fibrillation HPO | 0.50 |
Navigate: Correlations HPO
There is one clinical trial.
Newborns and infants receive passive natural immunity through maternal antibodies present in breastmilk to fight infections caused by viruses such as the COVID-19, until they develop active immunity by illness or vaccination. Such immunity will become the main stay for preventing future waves of COVID-19 epidemics. The high COVID-19 mortality among African Americans is ascribed partly to compromised immune status associated with comorbidity. Exclusive breastfeeding (EBF) is the effective low-cost natural strategy for building immunity right from birth. African Americans record the lowest EBF rates and also lack workplace support. This intervention includes a 10-hour course extracted from 90-hour CLC online program, sufficient to prepare physicians to partner with certified lactation consultant (CLC) to provide their patients comprehensive COVID-19 breastfeeding guidelines, training, and support to afford their babies the benefits of breastmilk antibodies, the best line of defense against COVID-19, until availability of safe vaccines. The Breastfeeding Report Card indicates slow improvements in overall breastfeeding rates with persisting disparities. Improving EBF rates can contribute to increased COVID-19 immunity among infants. Preliminary data in Nashville indicates excellent breastfeeding benefit knowledge and intent, but limited training to succeed. Hospital staff encourage breastfeeding but routinely offer formula at birth. Most physicians who provide prenatal care do not actively promote breastfeeding nor routinely offer CLC referral. This single action by physicians can halt routines that compromise successful EBF. The program long-term goal is to prepare obstetricians to actively promote comprehensive breastfeeding among African American mothers. The immediate objective is to develop and evaluate feasibility and effectiveness of an intervention designed to increase COVID-19 breastfeeding guideline adherence and improve EBF skills and rates among African American mothers. The rationale is that mothers who receive physician prenatal encouragement and CLC referral will make confident informed decisions, adopt COVID-19 breastfeeding guidelines, safely meet their EBF goals, and provide their infants with appropriate antibodies. The expected outcome is that patient participants will adhere to COVID-19 breastfeeding guidelines and record 3-month EBF rate 60 percent or greater.
Description: Percentage of participants who recorded an adherence score of 4 and above during the first week of birth. Range: 0 to 100.
Measure: COVID-19 breastfeeding guidance adherence at birth. Time: At birth.Description: Percentage of participants who recorded an adherence score of 4 and above at 1-month postpartum. Range: 0 to 100.
Measure: COVID-19 breastfeeding guidance adherence at 1-month postpartum. Time: At 1-month postpartum.Description: Percentage of participants who recorded an adherence score of 4 and above at 3-months postpartum. Range: 0 to 100.
Measure: COVID-19 breastfeeding guidance adherence at 3-months postpartum. Time: At 3-months postpartum.Description: Percentage of participants who exclusively breastfed at birth. Range: 0 - 100.
Measure: Exclusive breastfeeding at birth. Time: At birth.Description: Percentage of participants who exclusively breastfed at 1-month postpartum. Range: 0 - 100.
Measure: Exclusive breastfeeding at 1-month. Time: At 1-month.Description: Percentage of participants who exclusively breastfed at 3-months postpartum. Range: 0 - 100.
Measure: Exclusive breastfeeding at 3-months. Time: At 3-months.Description: Infant COVID-19 test: Positive or Negative
Measure: COVID_Status Time: 3-months postpartumDescription: Infant COVID-19 Immunoglobulin G serology test result.
Measure: COVID-19 Immunoglobulin G Time: 3-months postpartumDescription: Infant COVID-19 Immunoglobulin M serology test result.
Measure: COVID-19 Immunoglobulin M Time: 3-months postpartumDescription: Percentage of patients who consulted a Certified Lactation Consultant before delivery. Range: 0 - 100
Measure: Certified Lactation Consult in pregnancy. Time: At Birth.Description: Percentage of patients who consulted a Certified Lactation Consultant up to 1-month postpartum. Range: 0 - 100
Measure: Certified Lactation Consult after delivery. Time: At 1-month postpartum.Description: Change in pre- and post-intervention COVID-19 breastfeeding guideline knowledge score stratified to "Low" & "High".
Measure: COVID-19 breastfeeding guideline knowledge score change. Time: 1-month postpartumAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports